Caribou Biosciences, Inc. announced a strategic shift focusing on its lead oncology programs, CB-010 and CB-011, involving workforce and cost reductions aimed at extending its cash runway into the ...

-- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design -- -- CB-011 ...

Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026 Enacted ~30% workforce reduction to ...

FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--iQor, a leading managed services provider of digitally enabled business process outsourcing solutions, today announced a rigorous IT prioritization process ...